Compare Global X Lithium & Battery Tech ETF (LIT) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Lithium & Battery Tech ETF vs Merck & Co., Inc. — how do they compare? Global X Lithium & Battery Tech ETF trades at $69.73 (market cap $1.45B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 242.3× Global X Lithium & Battery Tech ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Global X Lithium & Battery Tech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Lithium & Battery Tech ETF for 56 Days and Merck & Co., Inc. for 98 Days on average.
| LIT | MRK | |
|---|---|---|
Market Cap | $1.45B | $351.28B |
Volume | 89,392 | 7,969,665 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $91.62 | $156.43 |
52-Week Low | $53.92 | $82.49 |
Typical Hold Time | 56 Days | 98 Days |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LIT (Global X Lithium & Battery Tech ETF) trades at $69.02, down 0.7% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages and oscillators. The ETF's recent performance reflects ongoing volatility in lithium markets, with short interest dropping 53.1% in September 2026. Recent news highlights continued growth in electric vehicle adoption and China's ambitious 30% NEV fleet target by 2030, supporting long-term battery technology demand.
The ETF presents exposure to the growing battery technology sector with strong catalysts from EV adoption and energy storage markets. However, investors face risks from lithium price volatility, Chinese export controls on critical minerals, and geopolitical trade tensions that could impact supply chains and performance.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
